Pfenex and Alvogen Announce European Medicines Agency Accepts Marketing Authorization Application for PF708
May 30, 2019 08:00 ET
|
Pfenex, Inc.
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization...
Pfenex Reports First Quarter 2019 Results and Provides Business Update
May 09, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Announce First Quarter 2019 Financial Results on May 9
April 25, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, April 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board
April 23, 2019 08:05 ET
|
Pfenex, Inc.
SAN DIEGO, April 23, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced the appointment of Robert Peach, Ph.D. to the Pfenex Scientific Advisory Board. “We are very excited...
Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act
April 11, 2019 08:05 ET
|
Pfenex, Inc.
SAN DIEGO, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
March 27, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Present at the 18th Annual Needham Healthcare Conference
March 26, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, March 26, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference
March 18, 2019 16:05 ET
|
Pfenex, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer
March 18, 2019 08:05 ET
|
Pfenex, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
March 11, 2019 16:05 ET
|
Pfenex, Inc.
We believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors Several significant milestones across the Company’s pipeline are expected in 2019 ...